Paying attention to the exact order in which you eat your food may give you an additional edge in optimising your health.

GLP-1 class of weight loss and diabetes drugs are linked to previously unrecognized health risks and benefits, according to a ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have other untapped potentials to reduce health risks.

Haemagglutination inhibition (HAI) antibody titres in primary infections peak at 1:640 whereas titres of 1: ... compliant with Good Laboratory Practice (GLP). Each specimen in the panel should ...

A study by Washington University School of Medicine and the VA St. Louis Health Care System has found that GLP-1 drugs can have both health benefits and risks, including reduced risks of ...

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

In Connecticut, where Medicaid has clamped down on covering GLP-1 medications for obesity, people are looking for alternatives. To make ends meet, some of Reshma Ramachandran’s patients at a ...

These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...